Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 3, 2012, Pages 352-355

  El Desoky, E S ^a   Sabarinath, S N ^b   Hamdi, M M ^a   Bewernitz, M ^b   Derendorf, H ^b  

^a Assiut University Faculty of Medicine   (Egypt)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

carbamazepine; epilepsy; population pharmacokinetic

Indexed keywords

CARBAMAZEPINE;

ADOLESCENT; ADULT; ARTICLE; BOOTSTRAPPING; CHILD; COMPARTMENT MODEL; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; EGYPT; EPILEPSY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; POPULATION MODEL; POPULATION RESEARCH; STEADY STATE; SUSPENSION; TABLET;

ADOLESCENT; ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; EGYPT; EPILEPSY; FEMALE; HUMANS; INFANT; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; SUSPENSIONS; TABLETS; YOUNG ADULT;

EID: 84861329756     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01296.x     Document Type: Article

References (29)

1. Anderson GD, (2008) Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Therapeutic Drug Monitoring, 30, 173-180.
2. Park PW, Seo YH, Ahn JY, Kim KA, Park JY, (2009) Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. Journal of Clinical Pharmacy and Therapeutics, 34, 569-574.
3. Eadie MJ, (1998) Therapeutic drug monitoring-antie pileptic drugs. British Journal of Clinical Pharmacology, 46, 185-193.
4. EL Desoky ES, AL-Ghamdi HA, Halaby FH, AL-Beshri M, (2003) Therapeutic monitoring of digoxin and antiepileptic drugs in Egypt and Saudi Arabia. Therapeutic Drug Monitoring, 25, 211-214.
5. EL Desoky ES, Kandil MR, (2002) Bayesian estimation of six different sets of carbamazepine pharmacokinetic parameters in Egyptian adult epileptic patients. Pharmacological Research, 45, 113-118.
6. Delgado Iribarnegaray MF, Santo Bueldga D, García Sánchez MJ, Otero MJ, Falcão AC, Domínguez-Gil A, (1997) Carbamazepine population pharmacokinetics in children: mixed-effect models. Therapeutic Drug Monioring, 19, 132-139.
7. Morselli PL, Franco-Morselli R, (1980) Clinical pharmacokinetics of antiepileptic drugs in adults. Pharmacology and Therapeutics, 10, 65-101.
8. Lotrich FE, Bies RR, Smith GS, Pollock BG, (2006) Relevalnce of assessing drug concentration exposure in pharmacogenetic and imaging studies. Journal of Psychopharmacology, 20, 33-40.
9. Miller R, Ludden TM, (1993) Bioavailability of controlled release carbamazepine estimated by mixed effect modeling. European Journal of Clinical Pharmacology, 44, 231-235.
10. Reith DM, Hooper WD, Parke J, Charles B, (2001) Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. Journal of Pharmacokinetics and Pharmacodynamics, 28, 79-92.
11. Carlsson KC, Hoem NO, Glauser T, Vinks AE, (2005) Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from patients with epilepsy. Clinical Therapeutics, 27, 618-626.
12. Jankovic SM, Jovanovic D, Milovanovic JR, (2008) Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. Methods and Findings in Experimental and Clinical Pharmacology, 30, 707-713.
13. Hockings N, Pall A, Moody J, Davidson AV, Davidson DL, (1986) The effects of age on carbamazepine pharmacokinetics and adverse effects. British Journal of Clinical Pharmacology, 32, 232-236.
14. Yukawa E, Aoyama T, (1996) Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. Journal of Clinical Pharmacology, 36, 752-759.
15. Jiao Z, Zhong MK, Shi XJ, Hu M, Zhang JH, (2003) Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Therapeutic Drug Monitoring, 25, 279-286.
16. Jiao Z, Shi XJ, Zhao ZG, Zhong MK, (2004) Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data. Journal of Clinical Pharmacology and Therapeutics, 29, 247-256.
17. Summers B, Summers RS, (1989) Carbamazepine clearance in pediatric epilepsy patients. Influence of body mass, dose, sex and co-medication. Clinical Pharmacokinetics, 17, 208-216.
18. Hartley R, Forsythe WI, McLain B, Ng PC, Lucock MD, (1991) Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children. Clinical Pharmacokinetics, 20, 237-246.
19. Wilding IR, Davis SS, Hardy JG, et al. (1991) Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. British Journal of Clinical Pharmacology, 32, 573-579.
20. Huf R, Schain RJ, (1980) Long-term experience with carbamazepine (Tegretol) in children with seizures. Journal of Pediatrics, 97, 310-312.
21. Schain RJ, War JW, Guthrie D, (1977) Carbamazepine as an anticonvulsant in children. Neurology, 27, 476-480.
22. Giessmann T, May K, Modess C, et al. (2004) Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clinical Pharmacology and Therapeutics, 76, 192-200.
23. Christians U, Schmitz V, Haschke M, (2005) Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opinion Drug Metabolism and Toxicology, 1, 641-654.
24. Loscher W, Klotz U, Zimprich F, Schmidt D, (2009) The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia, 50, 1-23.
25. Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A, (1999) Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatric Neurology, 21, 731-734.
26. Lazarowski A, Massaro M, Schteinschnaider A, Intruvini S, Sevlever G, Rabinowicz A, (2004) Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy. Threapeutic Drug Monioring, 26, 44-46.
27. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'Giano C, (2007) ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia, 48 (Suppl 5), 140-149.
28. Simon C, Stieger B, Kullak-Ublick GA, et al. (2007) Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurologica Scandinavica, 115, 232-242.
29. Rambeck B, May T, Juergens U, (1987) Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and co-medication. Therapeutic Drug Monitoring, 9, 298-303.